Amaros key facts
as of Oct 2026- Developer of an AI-powered platform designed to support clinical and post-market decision-making in ophthalmology.
- Amaros is valued at approximately $4.7M as of Oct 2026 (last reported valuation).
- It has raised $2.0M across 1 recorded rounds; the latest was Seed Round ($1.3M) in Mar 2025.
- Notable investors include Wilson Sonsini Goodrich & Rosati, Hero House (Armenia), SmartGateVC, Yoshimei.
- Amaros has filed 1 Form D with the SEC, most recently Apr 2025 ($1.3M sold to 11 investors).
- Status: Privately Held (backing).
Amaros's last reported valuation, Jul 2019. Nothing priced has surfaced since.
- ·Watch Amaros: the Monday email on marks, rounds and moves
Amaros funding rounds
1 roundsAmaros valuation
Amaros's last reported valuation was $4.7 million in Jul 2019. No priced round, secondary trade or fund mark has surfaced since.
How much has Amaros raised?
Amaros has raised $2 million in total; 1 of its rounds is on record. The largest on record was a $1.3 million seed round in Mar 2025.
Amaros has filed 1 Form D with the SEC, most recently in Apr 2025 ($1.3 million sold to 11 investors).
Amaros investors
4 investors are on record for Amaros, including Wilson Sonsini Goodrich & Rosati, Hero House (Armenia), SmartGateVC and Yoshimei. The seed round in Mar 2025 drew 11 investors.
About Amaros
Developer of an AI-powered platform designed to support clinical and post-market decision-making in ophthalmology. The company's platform collects, structures, and analyzes large datasets to accelerate clinical trial enrollment, generate real-world evidence, and identify market opportunities for life sciences companies, enabling clients to get access to faster and more informed therapeutic development methods.
- Sector
- Healthcare
- HQ
- Atherton, CA, United States
- Founded
- 2019
- Employees
- 14
- Website
- amaros.ai/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.